AbbVie (ABBV)

AbbVie is a quality pharmaceutical company that passed its biggest test: the post-Humira transition. Skyrizi and Rinvoq not only replaced the fallen top-selling drug but re-accelerated revenue, though the two already make up ~42% of total net revenue combined. It is a very high-margin business with substantial cash flow (~$17.8bn of real FCF), immunology leadership, a dominant aesthetics brand (Botox), and a deep pipeline (~90 compounds in development). The risks are the patent expiration (2033, with Rinvoq's extension to 2037 still conditional), price reform, the patent litigation already active in the neuroscience franchise, and the debt from the acquisitions — known and discountable, not a broken franchise.

It is valued on P/E over normalized adjusted earnings, not GAAP: GAAP earnings ($2.36 EPS) are pure noise — ~$7.4bn/year of Allergan intangible amortization and up to $6.5bn/year from the fair-value increase charge on contingent consideration (tied to Skyrizi's success), both non-cash, are embedded in cost — and the FY2025 adjusted figure ($10.00) was additionally depressed by a spike in pipeline spend (IPR&D $2.76/share). The normalized figure is ~$12.4 (close to the real FCF of ~$17.8bn). Net income delivers equity directly; total debt ~$65bn (net debt ~$63bn from the acquisitions) is reflected in earnings via interest.

The base scenario projects a value of ~$292 per share in five years, an annual return of ~+5% from the current ~$266. At ~$266 (near the high, after rallying from the $185 low) it trades at ~18× forward adjusted earnings (FY2026 ~$14) — above its ~15× historical average but below LLY (33×) and JNJ (22×). As earnings grow ~7% (Skyrizi/Rinvoq + aesthetics/oncology) and the multiple is disciplined toward ~16× (~15×, on the 2033 patent expiration), the return is made up of modest appreciation + the dividend (~2.7%).

The verdict is Fairly valued: It trades close to intrinsic value, far from the required margin of safety.. The successor thesis has already de-risked (Skyrizi + Rinvoq = 5.7× Humira), and the market recognized it: ABBV rallied from the low ($185) to ~$266 (near the high), at ~18× forward adjusted earnings — above its own history. The expected return (~+5%) comes from ~7% growth + the dividend (~2.7%), with the multiple disciplined toward ~16× on Skyrizi's 2033 patent expiration, which the market will begin to discount. The margin is moderate: a quality business with real growth, but at a full price after the rally — the bargain from the transition has already been captured.

The central disconfirmer: do the pipeline and the acquisitions build the next generation of franchises before Skyrizi/Rinvoq protection expires (2033 base case, 2037 only if Rinvoq's pediatric exclusivity is confirmed)? The signals: the growth of Skyrizi + Rinvoq — already ~42% of total net revenue — (does it hold above 20%?), pipeline progress (~90 compounds: next-generation immunology, the obesity bet, oncology), and an aesthetics recovery (Botox growing but Juvederm declining). And the underlying risks: Medicare price reform (Imbruvica/Vraylar/Botox) and the new antitrust suit over Humira rebates, the patent litigation AbbVie is already fighting over Ubrelvy and Qulipta, the ~$65bn of debt with maturities concentrated in 2029, and whether the acquisitions (after the emraclidine failure) pay off.